311 results on '"Qian, Wendi"'
Search Results
2. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
3. PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
4. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma
5. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
6. Study Protocol: The Use of Rituximab in Nephrotic Glomerulonephritis (TURING)
7. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
8. 497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial
9. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
10. PROphylaxis for vulnerable paTiEnts at risk of COVID-19 infecTion (PROTECT-V) – Sotrovimab arm
11. Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report
12. Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit
13. Bayes methods in group sequential clinical trials
14. Trajectories of Haemoglobin and incident stroke risk: a longitudinal cohort study
15. PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
16. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib
17. Patient reported outcome measures (PROMs) following forward planned field-in field IMRT: Results from the Cambridge Breast IMRT trial
18. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
19. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
20. Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial
21. Abstract OT2-24-01: PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
22. Bayes methods in group sequential clinical trials
23. Establishment of a validated central reading system for ileocolonoscopy in an academic setting
24. Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib
25. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
26. Immediate Versus Delayed Palliative Thoracic Radiotherapy In Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer And Minimal Thoracic Symptoms: Randomised Controlled Trial
27. Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma
28. The 3+3 versus model-based approach: implementation in the CAPCISUM pancreatic cancer trial
29. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
30. Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib.
31. ctDNA detection by personalised assays in early-stage NSCLC
32. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
33. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
34. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
35. Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: Based on Data from the Medical Research Council LU19 Trial
36. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
37. Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) – a single-arm phase 2a study of gemcitabine (Gem) plus Nab-paclitaxel (NabP) for borderline (un)resectable pancreatic ductal adenocarcinoma (BrPDAC)
38. Trimodality therapy for oesophageal cancer; why are we being so timid?: C02
39. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL
40. Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma
41. A Phase 3 Trial of Bevacizumab in Ovarian Cancer
42. Abstract 736: ctDNA detection in early stage non-small cell lung cancer
43. Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
44. Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
45. Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center
46. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial
47. Speeding up the Evaluation of New Agents in Cancer
48. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
49. Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multicenter Randomized LU21 Trial
50. Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.